which glp 1 is best for kidney disease Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Disease: A Narrative Review of the Key Evidence with Practical Considerations | Diabetes Therapy GLP-1 and the kidney: from

NEW real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) do not increase the risk of acute pancreatitis and may be associated with improved outcomes in patients with Type 2 diabetes who develop the condition

Although findings from clinical studies are promising, there are concerns that long-term exposure of GLP-1 RAs at supratherapeutic or maximum approved maintenance doses may impair muscle cell differentiation and potentially contribute to the development of sarcopenia, despite their potential to improve muscle metabolism and quality [83, 88]

But we also need to closely look into it because it involves issues of conduct, integrity, and reputation of the Institution, and matters that concern health and safety, Binay said

Retrieved 6 November 2022